文献速递胸部肿瘤放疗放疗物理与技术

巩固免疫检查点抑制剂改变NSCLC放化疗后心脏亚区放射敏感性

Consolidation ICIs Alter cardiac subregion radiosensitivity in NSCLC patients treated with Chemo-Radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-11-13

本研究回顾性分析321例局部晚期NSCLC根治性放化疗患者(其中67例接受巩固ICI),评估ICI暴露是否改变与放射性心脏病相关的关键心脏亚区。全组53例(18.4%)发生RIHD,两组无显著差异;CRT组窦房结剂量与RIHD风险相关,CRT+ICI组左心室剂量为显著预测因子。

要点

  • CRT组窦房结及心脏基底部剂量与RIHD风险独立相关。
  • CRT+ICI组左心室剂量为RIHD显著预测因子。
  • 两组RIHD发生率无显著差异,心脏亚区剂量相近。

核心结论

  • CRT患者中窦房结和心脏基底部剂量与RIHD相关,而CRT+ICI患者中左心室剂量与RIHD相关。

研究设计与样本

  • 心脏轮廓包括全心、心腔、主要冠状动脉和传导节点,主要终点RIHD定义为主要不良心脏事件和心房颤动。
  • 采用Fine-Gray分析探讨RIHD与心脏亚区平均剂量的关联。

主要发现

  • 全组53例(18.4%)发生RIHD,CRT组与CRT+ICI组之间无显著差异。
  • 两组心脏亚区剂量相似。
  • CRT组多变量分析显示心脏基底部尤其窦房结剂量与RIHD风险增加相关(HR=1.02每1 Gy,95%CI[1.01-1.03],p<0.001)。
  • CRT+IO组左心室剂量为显著预测因子(HR=1.06,95%CI[1.06-1.1],p=0.006)。

关键数值与推荐

  • CRT组窦房结剂量每增加1 Gy,RIHD风险HR=1.02(95%CI[1.01-1.03],p<0.001)。
  • CRT+IO组左心室剂量每增加1 Gy,RIHD风险HR=1.06(95%CI[1.06-1.1],p=0.006)。
  • 全组RIHD发生率为18.4%(53/321)。

临床怎么用

  • CRT患者放疗计划优化时应关注窦房结和心脏基底部剂量限制。
  • 接受巩固ICI的患者应特别关注左心室剂量限制。
  • 尽管每Gy风险增幅仅2-6%,但亚区结构小,精心优化计划可完全避开。

局限性

  • 回顾性研究设计。
  • ICI组样本量较小(67例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: he addition of immune checkpoint inhibitor (ICI) as consolidation therapy after chemoradiation (CRT) has improved survival rates in non-small cell lung cancer (NSCLC) patients. However, the cardiotoxicity of CRT combined with ICI remains underexplored. This study assesses if ICI exposure alters the critical cardiac subregion linked to radiation-induced heart disease (RIHD) following CRT. METHODS: We conducted a retrospective analysis of 321 locally advanced NSCLC patients treated with definitive CRT from August 2008 to December 2019, including 67 who received consolidation ICI. Cardiac contours include the entire heart, chambers, major coronary arteries, and conduction nodes. The primary endpoint was RIHD, defined as a major adverse cardiac event and atrial fibrillation. We used Fine-Gray analysis to investigate associations between RIHD and mean doses to cardiac subregions. RESULTS: In total, 53 patients (18.4 %) developed RIHD, with no significant difference between CRT and CRT + ICI groups. Doses to cardiac subregions were similar between the groups. In the CRT group, multivariable analysis shows that dose to the base of the heart, especially the sinoatrial node (SAN), correlated with increased RIHD risk (HR = 1.02 per 1 Gy, 95 %CI [1.01-1.03], p < 0.001). In the CRT + IO group, the left ventricle (LV) dose was a significant predictor (1.06 [1.06-1.1], p = 0.006). CONCLUSIONS: Doses to the SAN and the base of the heart correlate with RIHD in CRT patients, while doses to LV in CRT + ICI patients. While the 2-6 % increased risk per Gy seems modest, it is clinically significant as the subregions, being small structures, can potentially be completely spared with a carefully optimized plan.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Yang G, Oh J, et al. Consolidation ICIs Alter cardiac subregion radiosensitivity in NSCLC patients treated with Chemo-Radiotherapy. Clin Transl Radiat Oncol. 2025. PMID: 41334110. doi:10.1016/j.ctro.2025.101069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。